FY2027 Earnings Estimate for ACAD Issued By Leerink Partnrs

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Analysts at Leerink Partnrs cut their FY2027 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research note issued on Sunday, November 17th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of $1.50 for the year, down from their previous forecast of $1.60. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.15 EPS.

Several other research analysts also recently commented on ACAD. StockNews.com downgraded ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. UBS Group cut their price target on ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. Finally, Royal Bank of Canada cut their price target on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $25.56.

ACADIA Pharmaceuticals Stock Down 0.6 %

ACAD opened at $16.18 on Wednesday. The stock’s fifty day moving average is $15.61 and its two-hundred day moving average is $15.99. The company has a market capitalization of $2.69 billion, a P/E ratio of 20.74 and a beta of 0.38. ACADIA Pharmaceuticals has a 52 week low of $14.15 and a 52 week high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. During the same period in the prior year, the business posted ($0.40) earnings per share. The company’s revenue for the quarter was up 18.3% on a year-over-year basis.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ACAD. Sei Investments Co. increased its stake in shares of ACADIA Pharmaceuticals by 6.2% in the 1st quarter. Sei Investments Co. now owns 34,752 shares of the biopharmaceutical company’s stock valued at $642,000 after purchasing an additional 2,034 shares in the last quarter. Russell Investments Group Ltd. increased its stake in ACADIA Pharmaceuticals by 12.3% during the 1st quarter. Russell Investments Group Ltd. now owns 20,689 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 2,264 shares in the last quarter. ProShare Advisors LLC increased its stake in ACADIA Pharmaceuticals by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 33,583 shares of the biopharmaceutical company’s stock worth $621,000 after buying an additional 3,048 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in ACADIA Pharmaceuticals by 15.3% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 39,881 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 5,300 shares in the last quarter. Finally, Edgestream Partners L.P. increased its stake in ACADIA Pharmaceuticals by 63.3% during the 1st quarter. Edgestream Partners L.P. now owns 61,906 shares of the biopharmaceutical company’s stock worth $1,145,000 after buying an additional 23,998 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Activity

In other news, CFO Mark C. Schneyer sold 10,259 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $172,453.79. Following the completion of the transaction, the chief financial officer now owns 53,302 shares of the company’s stock, valued at $896,006.62. The trade was a 16.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Brendan Teehan sold 10,329 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $173,630.49. Following the completion of the transaction, the chief operating officer now owns 62,105 shares of the company’s stock, valued at approximately $1,043,985.05. This represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,661 shares of company stock valued at $414,551 in the last quarter. 28.30% of the stock is currently owned by company insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.